France-based Sanofi has agreed to acquire United States-based Synthorx, a company focused on developing therapies for cancer and autoimmune disorders, in order to strengthen its immuno-oncology pipeline, it was reported yesterday.
The deal is valued at USD2.5bn in cash. Sanofi is offering to purchase the company at USD68 per share.
The French company is likely to complete the transaction in the first quarter of 2020, which will be subject to the satisfaction or waiver of customary closing conditions.
THOR-707, Synthorx's lead immuno-oncology product candidate, is currently in clinical development in multiple solid tumour types. The interleukin-2 (IL-2) variant is being assessed as a single agent and also in combination with immune checkpoint inhibitors. Sanofi believes that THOR-707 can potentially become the best IL-2 therapeutic for the treatment of solid tumours and deliver improved pharmacology, therapeutic superiority and also less frequent dosing when compared to other IL-2 compounds.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial